of activating the immune response against tumor cells.
Clinically used checkpoint inhibition using antibodies
Fedorova, Yu. Yu.,
Aminova, E.T.,
Faishanova, R.R.,
Zagitov, I.R.,
Romanova, A.R.,
Nurgalieva, A.Kh.,
Andreeva, E.A.,
Darvish, M.,
Khusnutdinova, E.K.,
Prokofyeva, D.S. (2025) cancer and various histological and
clinical characteristics by MS-HRM method. Our results indicate a
. These results have been confirmed by
clinical studies. The purpose of this review was to systematize
clinical variability of the disease, even among members of the same family, several studies have described
Beylerli, Ozal,
Shi, Huaizhang,
Begliarzade, Sema,
Shumadalova, Alina,
Ilyasova, Tatiana,
Sufianov, Albert (2024) diagnostic tools and therapeutic targets. Further
clinical studies are imperative to validate the specificity
Fedorova, Yu Yu,
Sagitova, A.V.,
Mingazheva, E.T.,
Faishanova, R.R.,
Zagitov, I.R.,
Andreeva, E.A.,
Nurgalieva, A.Kh.,
Khusnutdinova, E.K.,
Darvish, M.,
Prokofyeva, D.S. (2024) from patients with an established diagnosis of ovarian cancer and various histological and
clinical